Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Apr;54(4):337-44.
doi: 10.1007/s00262-004-0608-7. Epub 2004 Sep 24.

Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats

Affiliations

Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats

Claudia Maria Goetz et al. Cancer Immunol Immunother. 2005 Apr.

Abstract

Introduction: For treatment of malignant glioma, radioimmunotherapy has become a valuable alternative for more than 2 decades. Surprisingly, very little is known about the distribution of intralesionally administered labelled antibodies or fragments. We investigated the migration of labelled antibodies and antibody fragments injected into intact and partly resected C6-glioma in rats at different times after injection.

Materials and methods: Nine days after induction of a C6-glioma, 5 microl of 125I-labelled murine anti-tenascin antibodies (n = 31) or 125I-labelled fragments of anti-tenascin antibodies (n = 32) was injected slowly into the tumour (group I). In group II the tumour was subtotally resected 9 days after induction of the C6-glioma, and 24 h later the labelled antibodies (n = 30) or fragments (n = 12) were injected into the resection cavity. At 6, 24 or 48 h after the injection, animals were sacrificed, and brains removed. Distribution of labelled antibodies and fragments was determined by superimposing autoradiographs onto frozen sections and HE-stained neighbouring sections using a digital image analysing system.

Results: After injection into intact C6-glioma, labelled antibodies covered a maximum distance of 3.2 +/- 1.0, 4.1 +/- 1.9 and 4.8 +/- 0.9 mm after 6, 24 and 48 h, respectively; while labelled fragments were found at a distance of 6.7 mm (+/-1.1) after 24 h and 5.8 mm (+/-0.9) after 48 h (significant in univariate analysis). Following partial tumour resection, the respective distances at 24 h were 3 +/- 0.4 mm for anti-tenascin antibodies and 3.4 +/- 0.3 mm for Fab fragments.

Conclusion: After injection into C6-glioma, labelled fragments are able to cover a greater distance than labelled antibodies. Injection of antibodies and fragments 1 day after tumour resection results in reduced velocity of both antibodies and fragments.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
T1-weighted MR image of a rat brain in coronal orientation on day 8 after induction of C6-glioma. Tumour indicated with white arrows.
Fig. 2
Fig. 2
Sketch showing the matching of frozen sections (a) with corresponding autoradiographs (b) for further evaluation (c).
Fig. 3
Fig. 3
Coronal section of C6-glioma matched with autoradiograph (dark area) showing needle tract (white line), distance measurement (dotted line) and determination of the area of propagation (black line).
Fig. 4
Fig. 4
Maximum propagation of labelled antibodies and labelled fragments at different time points after injection in intact tumours.
Fig. 5
Fig. 5
Maximum propagation of labelled antibodies and labelled fragments at different time points after injection in subtotally resected tumours.

Similar articles

Cited by

  • Diffuse glioma growth: a guerilla war.
    Claes A, Idema AJ, Wesseling P. Claes A, et al. Acta Neuropathol. 2007 Nov;114(5):443-58. doi: 10.1007/s00401-007-0293-7. Epub 2007 Sep 6. Acta Neuropathol. 2007. PMID: 17805551 Free PMC article. Review.

References

    1. Aaslid R, Groger U, Patlak CS, Fenstermacher JD, Huber P, Reulen HJ. Fluid flow rates in human peritumoural oedema. Acta Neurochir Suppl (Wien) 1990;51:152. - PubMed
    1. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994;34:45. - PubMed
    1. Bashir R, Hochberg F, Oot R. Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery. 1988;23:27. - PubMed
    1. Behr TM, Wormann B, Gramatzki M, Riggert J, Gratz S, Behe M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res. 1999;5:3304s. - PubMed
    1. Bender H, Takahashi H, Adachi K, Belser P, Liang SH, Prewett M, Schrappe M, Sutter A, Rodeck U, Herlyn D. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res. 1992;52:121. - PubMed

Publication types